Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MK-8776 |
Synonyms | |
Therapy Description |
MK-8776 is a selective CHK1 inhibitor, which may enhance sensitivity of tumor cells to chemotherapeutic agents (PMID: 22203733, PMID: 23594139, PMID: 28957699). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-8776 | SCH900776|SCH-900776|MK8776 | CHK1 Inhibitor 18 | MK-8776 is a selective CHK1 inhibitor, which may enhance sensitivity of tumor cells to chemotherapeutic agents (PMID: 22203733, PMID: 23594139, PMID: 28957699). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01870596 | Phase II | Cytarabine MK-8776 | Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia | Completed | USA | 0 |